Our mechanistic studies—including transcriptomic analysis, ex vivo PBMCs and melanoma co-culture, and an in vivo immunocompetent mouse melanoma model—demonstrated that blockade of nNOS modulated the T cell immune profile and enhanced T cell activation, thereby influencing anti-tumor immunity. The gene discussed is NOS1; the disease is melanoma.